Posts tagged T-cells
Maxim ups Galena Biopharma price target to $4

Maxim Group raised its price target for Galena Biopharma (NASDAQ:GALE) to $4 from $1, saying the company has multiple programs moving forward, including NeuVax. The stock was quoted at $2.90 in afternoon trading on Dec. 2.

Read More
HCW starts Kiadis Pharma at buy

H.C. Wainwright has launched coverage of Kiadis Pharma NV (NXT AM:KDS) of Amsterdam with a “buy” rating and price target of €15. The stock closed at €10 on Friday.

“We view Kiadis as an innovator in hematopoietic stem cell transplantation (HSCT) space with significant upside for the long-term investor,” writes analyst Mark Breidenbach.

Read More